Developer docs
API playgroundTry for free, no card

Search company profiles

Nanospectra Biosciences

Full company profile

uuid00028w7

Namestring
Nanospectra Biosciences
Legal namestring
NANOSPECTRA BIOSCIENCES INC
Websiteurl
nanospectra.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Nanospectra Biosciences is a privately-held, clinical-stage nanomedicine company founded in 2002 and headquartered in Houston, Texas. The company develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors, leveraging nanoshell-related technology originated by its co-founders Naomi Halas (nanophotonics) and Jennifer West (bioengineering) out of Rice University.

The company's core technology centers on particle-mediated thermal ablation, in which systemically or locally delivered particles accumulate preferentially in tumor tissue and, upon external energy activation, produce localized heating that destroys malignant cells while sparing surrounding healthy tissue. This positions Nanospectra in the oncology device/drug-combination segment, targeting solid tumor indications.

The business remains pre-commercial, with no disclosed revenue, customers, or pricing models in the available data. Capital formation has been the primary operating signal: the firm has completed multiple exempt offerings and rounds spanning 2010 through March 2023, including a $3 million strategic investment from Sirtex Medical in 2020 and a March 2023 raise of approximately $6 million against a $10 million target. The leadership team is small (1-10 employees) and operating under an interim CEO (David Jorden, also Chairman), consistent with a development-stage organization channeling capital toward clinical and regulatory milestones rather than commercial scaling.

Short descriptiontext

Nanospectra Biosciences is a clinical-stage, privately-held Houston-based nanomedicine company founded in 2002 that develops particle-based therapies for the selective thermal destruction of solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
nanoparticle cancer therapy, photothermal tumor ablation, nanomedicine oncology, solid tumor treatment, thermal tumor destruction
Industry1 code
PRIMARYHLAKAFAG
Surgical Oncology
NAICS code2 codes
  • Research and Development in Nanotechnology541713
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Nanomedicine Oncology Therapy
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nanospectra Biosciences develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors. The company's nanomedicine platform delivers localized photothermal treatment using targeted nanoparticles activated to ablate malignant tissue while sparing surrounding healthy structures. Its lead program targets solid tumor indications through this minimally invasive, image-guided therapeutic approach.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Particle-based solid tumor therapy
CategoryOncology Therapeutics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German company developing NanoTherm, a superparamagnetic iron oxide nanoparticle therapy activated by an alternating magnetic field to thermally ablate solid tumors (notably glioblastoma and prostate cancer). Closest direct peer in nanoparticle-based tumor thermal destruction.

TypeDirect peer
Description

French clinical-stage nanomedicine company developing NBTXR3, hafnium oxide nanoparticles that enhance the efficacy of radiation therapy in solid tumors. Directly comparable nanomedicine oncology platform with similar development-stage profile.

3Celsion Corporation
TypeDirect peer
Description

Clinical-stage oncology company developing ThermoDox, a heat-activated liposomal doxorubicin that releases chemotherapy when tumor tissue is heated. Directly comparable heat-mediated oncology therapeutic platform.

TypeDirect peer
Description

Developer of Focal One and Ablatherm HIFU (high-intensity focused ultrasound) systems for prostate and other tumor ablation. Direct competitor in localized prostate tumor ablation, the same target indication as Nanospectra's lead work.

TypeDirect peer
Description

Commercial-stage developer of TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Directly competes with Nanospectra's particle-mediated approach in the focal prostate therapy market.

TypeBroad incumbent
Description

Commercial-stage interventional oncology company selling SIR-Spheres Y-90 microspheres for liver cancer. Existing strategic investor in Nanospectra and broader incumbent in radiation-based locoregional tumor therapy.

TypeBroad incumbent
Description

Medical device company selling the NanoKnife irreversible electroporation (IRE) system for soft-tissue tumor ablation. Broad incumbent in interventional oncology ablation overlapping Nanospectra's tumor-destruction category.

8Perseon Medical (formerly BSD Medical)
TypeDirect peer
Description

Developer of hyperthermia and thermal therapy systems used to heat tumor tissue in combination with radiation or chemotherapy. Direct peer in thermally mediated oncology treatment.

TypeEmerging player
Description

Developer of cryoablation platforms (ProSense) for breast, kidney, lung, and prostate tumors. Emerging competitor in the minimally invasive solid tumor ablation space.

TypeBroad incumbent
Description

Acquired BTG's interventional oncology business (TheraSphere Y-90, embolization). Large incumbent with overlapping capabilities in locoregional tumor therapy, relevant as potential strategic acquirer or partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanospectra Biosciences

Nanomedicine Oncology Therapynanospectra.com

Nanospectra Biosciences is a clinical-stage, privately-held Houston-based nanomedicine company founded in 2002 that develops particle-based therapies for the selective thermal destruction of solid tumors.

What Nanospectra Biosciences does

Nanospectra Biosciences is a privately-held, clinical-stage nanomedicine company founded in 2002 and headquartered in Houston, Texas. The company develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors, leveraging nanoshell-related technology originated by its co-founders Naomi Halas (nanophotonics) and Jennifer West (bioengineering) out of Rice University.

The company's core technology centers on particle-mediated thermal ablation, in which systemically or locally delivered particles accumulate preferentially in tumor tissue and, upon external energy activation, produce localized heating that destroys malignant cells while sparing surrounding healthy tissue. This positions Nanospectra in the oncology device/drug-combination segment, targeting solid tumor indications.

The business remains pre-commercial, with no disclosed revenue, customers, or pricing models in the available data. Capital formation has been the primary operating signal: the firm has completed multiple exempt offerings and rounds spanning 2010 through March 2023, including a $3 million strategic investment from Sirtex Medical in 2020 and a March 2023 raise of approximately $6 million against a $10 million target. The leadership team is small (1-10 employees) and operating under an interim CEO (David Jorden, also Chairman), consistent with a development-stage organization channeling capital toward clinical and regulatory milestones rather than commercial scaling.

Nanospectra Biosciences firmographics

Firmographics
Name
Nanospectra Biosciences
Legal name
NANOSPECTRA BIOSCIENCES INC
Website
https://nanospectra.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
Nanospectra Biosciences is a clinical-stage, privately-held Houston-based nanomedicine company founded in 2002 that develops particle-based therapies for the selective thermal destruction of solid tumors.
Ownership category
akta.pro rank

Nanospectra Biosciences industry classification

Industry
Product category
Nanomedicine Oncology Therapy
NAICS
Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAFAG
Surgical Oncology

Keywords

  • Nanoparticle cancer therapy
  • Photothermal tumor ablation
  • Nanomedicine oncology
  • Solid tumor treatment
  • Thermal tumor destruction

Where Nanospectra Biosciences is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Markets served

Nanospectra Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Nanospectra Biosciences product offering

Product offering

Core offering

Nanospectra Biosciences develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors. The company's nanomedicine platform delivers localized photothermal treatment using targeted nanoparticles activated to ablate malignant tissue while sparing surrounding healthy structures. Its lead program targets solid tumor indications through this minimally invasive, image-guided therapeutic approach.

Differentiator

Problem solved

Functional benefit

Products and services

  • Particle-based solid tumor therapy

Companies that use Nanospectra Biosciences

Customer profile

Ideal customer profiles1 record

Nanospectra Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nanospectra Biosciences partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Nanospectra Biosciences competitors and assessment

Company assessment

Direct peers

  • MagForce AG: German company developing NanoTherm, a superparamagnetic iron oxide nanoparticle therapy activated by an alternating magnetic field to thermally ablate solid tumors (notably glioblastoma and prostate cancer). Closest direct peer in nanoparticle-based tumor thermal destruction.
  • Nanobiotix: French clinical-stage nanomedicine company developing NBTXR3, hafnium oxide nanoparticles that enhance the efficacy of radiation therapy in solid tumors. Directly comparable nanomedicine oncology platform with similar development-stage profile.
  • Celsion Corporation: Clinical-stage oncology company developing ThermoDox, a heat-activated liposomal doxorubicin that releases chemotherapy when tumor tissue is heated. Directly comparable heat-mediated oncology therapeutic platform.
  • EDAP TMS: Developer of Focal One and Ablatherm HIFU (high-intensity focused ultrasound) systems for prostate and other tumor ablation. Direct competitor in localized prostate tumor ablation, the same target indication as Nanospectra's lead work.
  • Profound Medical: Commercial-stage developer of TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Directly competes with Nanospectra's particle-mediated approach in the focal prostate therapy market.
  • Perseon Medical (formerly BSD Medical): Developer of hyperthermia and thermal therapy systems used to heat tumor tissue in combination with radiation or chemotherapy. Direct peer in thermally mediated oncology treatment.

Broad incumbents

  • Sirtex Medical: Commercial-stage interventional oncology company selling SIR-Spheres Y-90 microspheres for liver cancer. Existing strategic investor in Nanospectra and broader incumbent in radiation-based locoregional tumor therapy.
  • AngioDynamics: Medical device company selling the NanoKnife irreversible electroporation (IRE) system for soft-tissue tumor ablation. Broad incumbent in interventional oncology ablation overlapping Nanospectra's tumor-destruction category.
  • Boston Scientific (Interventional Oncology / BTG): Acquired BTG's interventional oncology business (TheraSphere Y-90, embolization). Large incumbent with overlapping capabilities in locoregional tumor therapy, relevant as potential strategic acquirer or partner.

Emerging players

  • IceCure Medical: Developer of cryoablation platforms (ProSense) for breast, kidney, lung, and prostate tumors. Emerging competitor in the minimally invasive solid tumor ablation space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Nanospectra Biosciences social profiles

Digital presence

Nanospectra Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanospectra Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Nanospectra Biosciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanospectra Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanospectra Biosciences

What does Nanospectra Biosciences do?

Nanospectra Biosciences develops particle-based therapies designed for the selective and precise thermal destruction of solid tumors. The company's nanomedicine platform delivers localized photothermal treatment using targeted nanoparticles activated to ablate malignant tissue while sparing surrounding healthy structures. Its lead program targets solid tumor indications through this minimally invasive, image-guided therapeutic approach.

Is Nanospectra Biosciences a public or private company?

Nanospectra Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanospectra Biosciences founded?

Nanospectra Biosciences was founded in 2002. It employs 1 to 10 people.

Where is Nanospectra Biosciences based?

Nanospectra Biosciences is headquartered in Houston, United States, in the North America region.

Who are Nanospectra Biosciences's main competitors?

Direct peers on record are MagForce AG, Nanobiotix, Celsion Corporation, EDAP TMS, Profound Medical and Perseon Medical (formerly BSD Medical). Broad incumbents are Sirtex Medical, AngioDynamics and Boston Scientific (Interventional Oncology / BTG). IceCure Medical is listed as an emerging player.

Does Nanospectra Biosciences have an API?

No public API is recorded for Nanospectra Biosciences.

What industry is Nanospectra Biosciences in?

Nanospectra Biosciences's product category is Nanomedicine Oncology Therapy. Its primary akta.pro industry code is HLAKAFAG, Surgical Oncology. Its NAICS code is 541713 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Urology TimesEnrollment completed in trial of novel nanoparticle-based focal ablation therapyNanospectra Biosciences has completed patient enrollment for a pivotal trial of AuroLase, a novel nanoparticle-based focal ablation therapy for localized prostate cancer. The company anticipates initial 6-month results in mid-2022 and plans to file for FDA regulatory clearance by the end of next year.UVA TodayNanoparticle Therapy Offers New Hope for Prostate Cancer PatientsA multi-institutional study demonstrated that nanoparticle-directed focal photothermal ablation using gold nanoshells successfully eliminated cancerous cells in 73% of prostate cancer patients after 12 months. The therapy, which combines near-infrared laser treatment with MRI and ultrasound fusion, preserves urinary and sexual health without observed side effects. Nanospectra Biosciences Inc. is commercializing this technology developed by researchers from institutions including the University of Virginia.SecSEC FORM DNanospectra Biosciences Inc filed a Form D with the SEC for an exempt securities offering under Rule 506(b) with a total offering amount of approximately $10.07 million. The filing indicates that $6.07 million has been sold to 51 investors, with the remaining balance still available for sale. This regulatory submission discloses the company's ongoing capital raise activities.Business InsiderI'm a tech executive who moved from Silicon Valley to Houston. I know firsthand why the tech industry is packing up and hightailing it to Texas.A tech executive who moved from Silicon Valley to Houston explains why technology companies are relocating to Texas, citing lower costs and no state income tax. He notes industrial companies in Texas have secured $2.6 billion in venture capital over five years, and cites examples like SpaceX and Nanospectra.PR NewswireSirtex Medical announces strategic investment in Nanospectra BiosciencesSirtex Medical announced a strategic equity investment in Nanospectra Biosciences as part of the latter's Series B-1 financing round. In exchange for this investment and a board seat, Sirtex secured an exclusive right to negotiate access to Nanospectra's AuroLase Therapy for prostate cancer in non-U.S. geographies.PR NewswireNanospectra Biosciences Raises First Tranche of Series B-1 Funding Led by Sirtex MedicalNanospectra Biosciences has closed an initial $3 million tranche of a Series B-1 financing round with total approved capital of up to $6 million, led by Sirtex Medical as a strategic investor. Sirtex's General Counsel Kevin P. Smith will join Nanospectra's Board of Directors, and the proceeds will fund AuroLase development including completion of the pivotal prostate cancer study and FDA 510(k) submission for marketing clearance. The companies have also agreed to exclusively negotiate for a defined period for AuroLase access in certain geographies outside the United States.VC News DailyNanospectra Biosciences Inks First of Series B-1Nanospectra Biosciences has closed an initial $3 million in a Series B-1 financing, with a total approved capital of up to $6 million, aiming to develop their AuroLase technology for prostate cancer treatment. The equity round was led by Sirtex Medical, which will also join Nanospectra's Board of Directors. This collaboration is expected to enhance commercialization efforts for their target therapies in the U.S. and internationally.Built In14 Biotech Companies In Houston To KnowHouston is emerging as a major life sciences hub, boasting the third fastest-growing biotech community in the nation between 2014 and 2017 and attracting nearly $180 million in VC funding in 2019. The article profiles 14 local biotech companies, including Celltex Therapeutics, Moleculin Biotech, and Nanospectra Biosciences, highlighting their work in areas such as stem cell therapy, cancer treatment, and genomic medicine. These organizations are leveraging decades of research to develop novel medical solutions for conditions ranging from oncology to cardiovascular issues.PR NewswireNanospectra Biosciences Initiates Pivotal Study of AuroLase Therapy for Ablation of Prostate TissueNanospectra Biosciences has initiated a pivotal study for its AuroLase Therapy, a nanoparticle-directed laser ablation treatment for prostate tissue, with the first two patient procedures completed at the University of Michigan. The pivotal study follows a successful pilot study where 13 of the first 15 prostate cancer patients showed no detectable signs of cancer in the target ablation zone a year after treatment. The company plans to enroll up to 60 patients at up to eight clinical trial sites across the United States to assess the efficacy of focal ablation using MRI/ultrasound guided biopsy.